Protalix is a biopharmaceutical company focused on the development, production, and commercialization of innovative medicines for patients living with rare diseases. We are advancing promising candidates leveraging our expertise in protein therapeutics through our proprietary, commercial-scale ProCellEx® plant cell-based protein expression system, as well as our chemical and genetic modification capabilities, including PEGylation. With two approved drugs already making an impact, we are committed to expanding our pipeline to address the unmet needs of patients facing some of the most challenging rare diseases. At Protalix, our goal is to be at the forefront of transforming lives by developing groundbreaking solutions for rare diseases with high unmet need. Our unwavering dedication to patients living with rare diseases drives us forward, fueling our mission to deliver safe and effective solutions to individuals facing limited to no currently available therapeutic options.